Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
about
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerClinical experiences with molecular targeted therapy in lung cancer in ChinaNon-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancerAdvances of heterogeneity of EGFR in non-small cell lung cancerPhosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFRBlood-based Tumor Markers in Lung CancerBlood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-AnalysisA robust tool for discriminative analysis and feature selection in paired samples impacts the identification of the genes essential for reprogramming lung tissue to adenocarcinomaLung Cancer: Are we up to the Challenge?K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.Liquid biopsy genotyping in lung cancer: ready for clinical utility?Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer.Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer.Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day.Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients.Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer.Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients.Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation.Influence of chemotherapy on EGFR mutation status.Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung CancerPrevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma.Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lungERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations.Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitorsRandomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment.Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations.Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRASThe Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.[Preliminary Study of Differentially Expressed Serum Peptides of Advanced NSCLC Patients Responsive to EGFR-TKI and Their Clinical Significance].EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutationDetection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer.EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysisComparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation statusA prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.
P2860
Q26775376-E3DBA034-8935-4D0F-AE7E-8A4E25D741F1Q26798228-69A54FCE-F677-45DD-96E7-F601F4148461Q26801357-2D3886D2-15E2-4F9C-BEE6-1E2D8FCF9A4EQ26999714-B20C0E31-A5E4-4ADE-AF44-DA1A425B3D50Q27851872-A54E61A0-9845-458A-87FD-96E3BB372947Q28072736-086164FC-EB32-40A4-83B4-A2BC21858855Q28087366-7D9E18D5-1E0D-4439-A23C-6BF74DDBA4F3Q28385552-B420D546-525E-4884-8D36-7C8E3E518FF7Q28386607-DED1CCC7-9FE9-4E39-B97C-72B5A0024F14Q30250097-35EF9B32-9E44-4EBD-B26C-A243425C145BQ33567037-A434676A-8CDA-4855-8CC1-5E1AA88E3D53Q33582524-6D5DDFA9-4A07-4364-AD5E-D0D60A4CDB39Q33598423-6AE44BF3-A23D-4E0D-A7B5-F0303B4F81D9Q33735738-04D5F85C-AC3F-4DAF-87D1-5F494DC3D802Q33779727-20538960-3A39-46AE-861B-EF47ACAD642CQ33863388-EC62862D-64EC-4B39-B0B3-66788CED7148Q33903541-06E9F219-68A6-4654-8D5B-9EE9A0C9F188Q34092157-889BE77E-4F6D-4F3F-B562-50199F4A41A2Q34535332-962AA836-AD68-4D1A-A617-05CAB90996FAQ34589493-78317304-A37B-4F28-AD9E-EF278F87448DQ35034044-6EE2CBF4-1DFA-4C10-BFED-CD0DB73C9EE7Q35063579-7D6B28EA-4670-4AAC-84F1-AF935D20083BQ35159562-FEE60CFD-68F1-4509-9EEE-A4648A3AE8D4Q35200458-C0B3555A-3579-4D29-92A7-F4542755F8C7Q35654703-FE2906C2-3C53-4C1B-86F6-284DF9A4597EQ35663416-128567DA-03EB-4C36-9E6C-66E2D62C368EQ35663430-C227A4C8-1C3F-4C16-9197-235D946CCF38Q35764673-A0D2204B-04E2-44C2-A1AD-5EA4B9DBDC59Q35764712-3B676DFA-09D7-4091-A75D-EE540133BFAAQ35894882-FF84EFC6-0A00-4789-B74A-DA1A4477B595Q35961430-AFDE4506-B9FF-4B40-AD35-70EAB757B2C3Q36040606-452B37DE-19A2-4877-BECC-8AE7364C343BQ36095650-944D31BF-5957-4394-9001-14F9ABFCCB96Q36144126-E2362C31-F16A-49AE-BDFD-84BF825776D1Q36250691-4D6B0689-EF90-4205-B3D9-6834C85B4EDEQ36276264-2E3F8DB2-BA5A-4560-8064-D25D9BE539E1Q36278010-7B457C02-4346-4B2F-AE33-010FAD914F22Q36282366-6C6419FF-9CF4-4703-AAAF-8CF9D3D99C40Q36375343-68CA14E3-A837-4DB0-B15B-0A9DB5140B6DQ36384490-4D94BF62-7898-4E1F-A809-BD0EA2F8BE15
P2860
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Epidermal growth factor recept ...... IV non-small-cell lung cancer.
@en
Epidermal growth factor recept ...... IV non-small-cell lung cancer.
@nl
type
label
Epidermal growth factor recept ...... IV non-small-cell lung cancer.
@en
Epidermal growth factor recept ...... IV non-small-cell lung cancer.
@nl
prefLabel
Epidermal growth factor recept ...... IV non-small-cell lung cancer.
@en
Epidermal growth factor recept ...... IV non-small-cell lung cancer.
@nl
P2093
P356
P1476
Epidermal growth factor recept ...... IV non-small-cell lung cancer.
@en
P2093
Chun Jian Duan
Hang Shu Wang
Hong Ning Liu
Tong Tong An
P304
P356
10.1200/JCO.2008.17.3930
P407
P577
2009-05-04T00:00:00Z